MetaVia Inc. is trading 5.6% down at $1.61 as a post-Fed risk-off tone continues to weigh on speculative small-cap biotech names.
- The stock experienced a sharp pre-market slide following the June 17 Federal Reserve policy update and a subsequent rise in Treasury yields.
- While broader indices have begun to rebound into a risk-on session, MetaVia shares remain under pressure as investors reassess exposure to risk assets.